Developing an appropriate delivery vehicle for antisense oligonucleotides (AS-ODNs) to improve efficiency has been a central issue for translating antisense therapy into practice. We have proposed a macromolecular complex made from AS-ODNs and β-glucan, schizophyllan (SPG) as such a tool. We recently discovered a low molecular weight complex in which only one ODNs can be complexed and denoted it as a “quantized complex”. This quantized complex can transfer AS-ODNs into cytosol more efficiently than the conventional large molecular weight complexes. Building on this previous work, this paper presents a new idea of delivering two different AS-ODNs (K-ras and YB-1) simultaneously to the same target cell to synergistically suppress the growth of cancer cells.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hagedorn PH, Hansen BR, Koch T, Lindow M. Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Res. 2017;45:2262–82.
Khar R, Warsi M, Akhter S, Ahmad F, Jain G, Mallick N, et al. Nano-vectors for the ocular delivery of nucleic acid-based therapeutics. Indian J Pharm Sci. 2010;72:675.
Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280–4.
Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7:1209–26.
Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337–46.
Kim YT, Kim EH, Cheong C, Williams DL, Kim CW, Lim ST. Structural characterization of beta-D-(1 -> 3, 1 -> 6)-linked glucans using NMR spectroscopy. Carbohydr Res. 2000;328:331–41.
Adachi Y, Ishii T, Ikeda Y, Hoshino A, Tamura H, Aketagawa J, et al. Characterization of β-Glucan recognition site on C-Type Lectin, Dectin 1. Infect Immun. 2004;72:4159–71.
McIntire TM, Brant DA. Observations of the (1→3)-β-d-Glucan linear triple helix to macrocycle interconversion using noncontact atomic force microscopy. J Am Chem Soc. 1998;120:6909–19.
Sakurai K, Shinkai S. Molecular recognition of adenine, cytosine, and uracil in a single-stranded RNA by a natural polysaccharide: Schizophyllan. J Am Chem Soc. 2000;122:4520–1.
Mochizuki S, Sakaurai K. β-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression. Bioorg Chem. 2010;38:260–4.
Sumiya K, Matsunaga T, Tanaka M, Mochizuki S, Sakurai K. Oligo-DNA Stoichiometrically binds β-1,3-Glucan with the best fit length. Biomacromolecules. 2020;21:4823–34.
Sumiya K, Izumi H, Matsunaga T, Tanaka M, Sakurai K. Delivery of therapeutic oligonucleotides targeting Dectin-1 using quantized complexes. Polym J. 2022;54:591–601.
Izumi H, Nagao S, Mochizuki S, Fujiwara N, Sakurai K, Morimoto Y. Optimal sequence of antisense DNA to silence YB-1 in lung cancer by use of a novel polysaccharide drug delivery system. Int J Oncol. 2016;48:2472–8.
Fujiwara N, Izumi H, Morimoto Y, Sakurai K, Mochizuki S. Complex consisting of antisense DNA and β-glucan promotes internalization into cell through Dectin-1 and hybridizes with target mRNA in cytosol. Cancer Gene Ther. 2019;26:32–40.
Sasaki S, Izumi H, Morimoto Y, Sakurai K, Mochizuki S. Induction of potent cell growth inhibition by schizophyllan/K-ras antisense complex in combination with gemcitabine. Bioorg Med Chem. 2020;28:115668.
Yin Q, Zheng M, Luo Q, Jiang D, Zhang H, Chen C. YB-1 as an Oncoprotein: Functions, regulation, post-translational modifications, and targeted therapy. Cells. 2022;11:1217.
We gratefully would like to thank Takuya Matsunaga and Motoko Tanaka for technical help. This work was financially supported by JSPS KAKENHI and by JST: Grant-in-Aid for Scientific Research A (20H00668), Grant-in-Aid for Challenging Exploratory Research (20K20449), and Kitakyushu Innovative Human Resource and Regional Development Program (JPMJSP2149).
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hata, Y., Sumiya, K., Izumi, H. et al. Antisense DNA cocktail therapy using short ß-1,3-glucan/oligonucleotide complexes. Polym J (2022). https://doi.org/10.1038/s41428-022-00720-1